An update on TroVax^® for the treatment of progressive castration-resistant prostate cancer

References

• AltekruseSFKosaryCLKrapchoMSEER cancer statistics review, 1975–2007, based on November 2009 SEER data submissionBethesda, MDNational Cancer Institute http://seer.cancer.gov/csr/1975_2007/. Accessed April 20, 2011.
   Google Scholar
• JohanssonJEAndrénOAnderssonSONatural history of early, localized prostate cancerJAMA2004291222713271915187052
   PubMed Web of Science ®Google Scholar
• OefeleinMGFengAScolieriMJReassessment of the definition of castrate levels of testosterone: implications for clinical decision makingUrology20005661021102411113751
   PubMed Web of Science ®Google Scholar
• ScherHIKellyWZhangZFPost-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancerJ Natl Cancer Inst19999124410037102
   PubMedGoogle Scholar
• ChoDDi BlasioCJRheeACKattanMWPrognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT)Urol Oncol200321428229112954499
   PubMed Web of Science ®Google Scholar
• HalabiSSmallEJKantoffPWPrognostic model for predicting survival in men with hormone-refractory metastatic prostate cancerJ Clin Oncol20032171232123712663709
   PubMed Web of Science ®Google Scholar
• SmaletzOScherHISmallEJNomogram for overall survival of patients with progressive metastatic prostate cancer after castrationJ Clin Oncol200220397212351594
   PubMed Web of Science ®Google Scholar
• OefeleinMGAgarwalPKResnickMISurvival of patients with hormone refractory prostate cancer in the prostate specific antigen eraJ Urol200417141525152815017212
   PubMed Web of Science ®Google Scholar
• TherassePArbuckSGEisenhauerEANew guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of CanadaJ Natl Cancer Inst200092320521610655437
   PubMed Web of Science ®Google Scholar
• ScherHIHalabiSTannockIProstate Cancer Clinical Trials Working GroupDesign and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working GroupJ Clin Oncol20082671148115918309951
   PubMed Web of Science ®Google Scholar
• TannockIFde WitRBerryWRTAX 327 InvestigatorsDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerN Engl J Med2004351151502151215470213
   PubMed Web of Science ®Google Scholar
• BertholdDRPondGRSobanFDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 studyJ Clin Oncol200826224224518182665
   PubMed Web of Science ®Google Scholar
• SternbergCNPetrylakDPSartorOMultinational, double-blind, Phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trialJ Clin Oncol200927325431543819805692
   PubMed Web of Science ®Google Scholar
• GarciaJAHutsonTEShepardDGemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a Phase 2 trialCancer2011117475275720922803
   PubMed Web of Science ®Google Scholar
• De BonoJSOudardSOzgurogluMTROPIC InvestigatorsPrednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialLancet201037697471147115420888992
   PubMed Web of Science ®Google Scholar
• ReidAHAttardGDanilaDCSignificant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetateJ Clin Oncol20102891489149520159823
   PubMed Web of Science ®Google Scholar
• ScherHILogothetisCMolinaAImproved survival outcomes in clinically relevant patient subgroups from COU-AA-301, a Phase III study of abiraterone acetate (AA) plus prednisone (P) in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-based chemotherapy Genitourinary Cancers Symposium. Abstract 4. Presented February 17, 2011.
   Google Scholar
• NabhanCParsonsBTouloukianEZStadlerWMNovel approaches and future directions in castration-resistant prostate cancerAnn Oncol201112 [Epub ahead of print]
   Google Scholar
• PapacRJSpontaneous regression of cancerCancer Treat Rev19962263954239134002
   PubMed Web of Science ®Google Scholar
• YasumuraSLinWCWeidmannEExpression of interleukin 2 receptors on human carcinoma cell lines and tumor growth inhibition by interleukin 2Int J Cancer19945922252347523315
   PubMed Web of Science ®Google Scholar
• NegrierSEscudierBLassetCRecombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d’ImmunothérapieN Engl J Med199833818127212789562581
   PubMed Web of Science ®Google Scholar
• MackensenAMeidenbauerNVoglSPhase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanomaJ Clin Oncol200624315060506917075125
   PubMed Web of Science ®Google Scholar
• EylesJPuauxALWangXTumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanomaJ Clin Invest201012062030203920501944
   PubMed Web of Science ®Google Scholar
• SmallEJSchellhammerPFHiganoCSPlacebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancerJ Clin Oncol200624193089309416809734
   PubMed Web of Science ®Google Scholar
• HiganoCSSchellhammerPFSmallEJIntegrated data from 2 randomized, double-blind, placebo-controlled, Phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancerCancer2009115163670367919536890
   PubMed Web of Science ®Google Scholar
• KantoffPWHiganoCSShoreNDIMPACT Study InvestigatorsSipuleucel-T immunotherapy for castration resistant prostate cancerN Engl J Med2010363541142220818862
   PubMed Web of Science ®Google Scholar
• KaufmanHLWangWManolaJPhase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative GroupJ Clin Oncol200422112122213215169798
   PubMed Web of Science ®Google Scholar
• DiPaolaRSPlanteMKaufmanHA Phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7–1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancerJ Transl Med20064116390546
   PubMed Web of Science ®Google Scholar
• KantoffPWSchuetzTJBlumensteinBAOverall survival analysis of a Phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancerJ Clin Oncol20102871099110520100959
   PubMed Web of Science ®Google Scholar
• KrupaMCanameroMGomezCEImmunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progressionVaccine20112971504151321182993
   PubMed Web of Science ®Google Scholar
• FerraroBCisperNJTalbottKTCo-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responsesHum Vaccine2011117 [Epub ahead of print]
   Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilumimab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• FongLKwekSSO’BrienSPotentiating endogenous anti-tumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSFCancer Res200969260961519147575
   PubMed Web of Science ®Google Scholar
• HiganoCSCormanJMSmithDCPhase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancerCancer2008113597598418646045
   PubMed Web of Science ®Google Scholar
• HoleNSternPLA 72 kD trophoblast glycoprotein defined by a monoclonal antibodyBr J Cancer19885732392463355761
   PubMed Web of Science ®Google Scholar
• SouthallPJBoxerGMBagshaweKDImmunohistological distribution of 5T4 antigen in normal and malignant tissuesBr J Cancer199061189952404511
   PubMed Web of Science ®Google Scholar
• CarsbergCJMyersKASternPLMetastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cellsInt J Cancer199668184928895545
   PubMed Web of Science ®Google Scholar
• JonesHRobertsGHoleNInvestigation of expression of 5T4 antigen in cervical cancerBr J Cancer1990611961002404512
   PubMed Web of Science ®Google Scholar
• StarzynskaTRahiVSternPLThe expression of 5T4 antigen in colorectal and gastric carcinomaBr J Cancer19926658678691419629
   PubMed Web of Science ®Google Scholar
• WrigleyEMcGownATRennisonJ5T4 oncofetal antigen expression in ovarian carcinomaInt J Gynecol Cancer19955426927411578488
   PubMed Web of Science ®Google Scholar
• CarrollMWMossBHost range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell lineVirology199723821982119400593
   PubMed Web of Science ®Google Scholar
• BlanchardTJAlcamiAAndreaPSmithGLModified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccineJ Gen Virol199879Pt 5115911679603331
   PubMed Web of Science ®Google Scholar
• MossBCarrollMWWyattLSHost range restricted, non-replicating vaccinia virus vectors as vaccine candidatesAdv Exp Med Biol19963977138718576
   PubMedGoogle Scholar
• MulryanKRyanMGMyersKAAttenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumorsMol Cancer Ther20021121129113712481437
   PubMed Web of Science ®Google Scholar
• HarropRRyanMGMyersKAActive treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax®) is CD4+ T cell dependent and antibody mediatedCancer Immunol Immunother20065591081109016311730
   PubMed Web of Science ®Google Scholar
• HarropRConnollyNRedchenkoIVaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax®) induces immune responses which correlate with disease control: a Phase I/II trialClin Cancer Res20061211 Pt 13416342416740766
   PubMed Web of Science ®Google Scholar
• ElkordEDangoorADruryNLAn MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastasesJ Immunother200831982082918833005
   PubMed Web of Science ®Google Scholar
• HarropRDruryNShinglerWVaccination of colorectal cancer patients with TroVax® given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responsesCancer Immunol Immunother200857797798618060404
   PubMed Web of Science ®Google Scholar
• HarropRDruryNShinglerWVaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax®) given alongside chemotherapy induces potent immune responsesClin Cancer Res20071315 Pt 14487449417671134
   PubMed Web of Science ®Google Scholar
• HarropRShinglerWKelleherMCross-trial analysis of immunologic and clinical data resulting from Phase I and II trials of MVA-5T4 (TroVax®) in colorectal, renal, and prostate cancer patientsJ Immunother2010339999100520948436
   PubMed Web of Science ®Google Scholar
• KaufmanHLTabackBShermanWPhase II trial of modified vaccinia Ankara (MVA) virus expressing 5T4 and high dose interleukin-2 (IL-2) in patients with metastatic renal cell carcinomaJ Transl Med20097219128501
   PubMed Web of Science ®Google Scholar
• HawkinsREMacdermottCShablakAVaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax®) given alongside interferon-alphaJ Immunother200932442442919342962
   PubMed Web of Science ®Google Scholar
• AmatoRJShinglerWNaylorSVaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax®) administered with interleukin 2: a Phase II trialClin Cancer Res200814227504751019010868
   PubMed Web of Science ®Google Scholar
• AmatoRJShinglerWGoonewardenaMVaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax®) alone or administered in combination with interferon-alpha (IFN-alpha): a Phase 2 trialJ Immunother200932776577219561532
   PubMed Web of Science ®Google Scholar
• AmatoRJHawkinsREKaufmanHLVaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled Phase III studyClin Cancer Res201016225539554720881001
   PubMed Web of Science ®Google Scholar
• HarropRShinglerWMcDonaldMMVA-5T4 induced immune responses are an early marker of efficacy in renal cancer patientsCancer Immunol Immunother201139 [Epub ahead of print]
   Google Scholar
• AmatoRJDruryNNaylorSVaccination of prostate cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax®): a Phase 2 trialJ Immunother200831657758518528296
   PubMed Web of Science ®Google Scholar
• Study of TroVax® Plus Docetaxel Versus Docetaxel Alone in Patients with Progressive Hormone Refractory Prostate Cancer http://clinicaltrials.gov/ct2/show/NCT00521274. Accessed February 16, 2011.
   Google Scholar
• TroVax® in Subjects with Hormone Refractory Prostate Cancer (HRPC) http://clinicaltrials.gov/ct2/show/NCT01194960. Accessed February 16, 2011.
   Google Scholar
• WolchokJDHoosAO’DaySGuidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteriaClin Cancer Res200915237412742019934295
   PubMed Web of Science ®Google Scholar